Restoration of alveolar type II cell function contributes to simvastatin-induced attenuation of lung ischemia-reperfusion injury

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1294-1306

  Wu, Yaqin ^a   Lv, Junjie ^b   Feng, Dongjie ^a   Jiang, Feng ^a   Fan, Xiaohu ^c   Zhang, Zhi ^a   Yin, Rong ^a   Xu, Lin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alveolar type II cells; Apoptosis; Lung ischemia reperfusion injury; Proliferation; Simvastatin

Indexed keywords

CYCLINE; MEVALONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIMVASTATIN; SURFACTANT PROTEIN C; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG ALVEOLUS CELL TYPE 2; LUNG INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REOXYGENATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY;

ANDROSTADIENES; ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG; MALE; MEVALONIC ACID; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PNEUMOCYTES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SECRETORY VESICLES; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 84869467720     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1161     Document Type: Article

References (39)

1. Fujino N, Kubo H, Suzuki T, et al: Isolation of alveolar epithelial type II progenitor cells from adult human lungs. Lab Invest 91: 363-378, 2011.
2. Herzog EL, Brody AR, Colby TV, Mason R and Williams MC: Knowns and unknowns of the alveolus. Proc Am Thorac Soc 5: 778-782, 2008.
3. Wang D, Haviland DL, Burns AR, Zsigmond E and Wetsel RA: A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 104: 4449-4454, 2007. (Pubitemid 47186246)
4. Andreeva AV, Kutuzov MA and Voyno-Yasenetskaya TA: Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 293: L259-L271, 2007. (Pubitemid 47205004)
5. Mason RJ: Biology of alveolar type II cells. Respirology 11 (Suppl): S12-S15, 2006.
6. Neuringer IP and Randell SH: Stem cells and repair of lung injuries. Respir Res 5: 6, 2004.
7. Wang D, Morales JE, Calame DG, Alcorn JL and Wetsel RA: Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther 18: 625-634, 2010.
8. Feng D, Zhang S, Hu Z, Fan F, Jiang F, Yin R and Xu L: Dynamic investigation of alveolar type II cell function in a long-term survival model of rat lung ischemia-reperfusion injury. Scand J Clin Lab Invest 70: 364-373, 2010.
9. Shanes JG, Minadeo KN, Moret A, Groner M and Tabaie SA: Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J 154: 617-623, 2007. (Pubitemid 47432875)
10. Makris GC, Geroulakos G, Makris MC, Mikhailidis DP and Falagas ME: The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. Expert Opin Investig Drugs 19: 809-814, 2010.
11. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S and Mach F: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188: 51-58, 2006. (Pubitemid 44142533)
12. Undas A, Celinska-Lowenhoff M, Kaczor M and Musial J: New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 91: 1065-1077, 2004. (Pubitemid 38821261)
13. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C and Mulligan MS: Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 126: 482-489, 2003. (Pubitemid 37048516)
14. Muller HC, Hellwig K, Rosseau S, et al: Simvastatin attenuates ventilator-induced lung injury in mice. Crit Care 14: R143, 2010.
15. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR and Gajic O: Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 35: 1039-1046, 2009.
16. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS and McAuley DF: A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 183: 620-626, 2011.
17. Shyamsundar M, Craig T, O'Kane C and McAuley D: Comment on 'Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury'. Intensive Care Med 35: 1494-1495, 2009.
18. Takahashi S, Nakamura H, Seki M, et al: Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol 294: L882-L890, 2008.
19. Wolfrum S, Dendorfer A, Schutt M, et al: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355, 2004. (Pubitemid 39129454)
20. Bell RM and Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515, 2003. (Pubitemid 36164511)
21. Zeki AA, Franzi L, Last J and Kenyon NJ: Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180: 731-740, 2009.
22. Bussolati B, Deregibus MC, Fonsato V, et al: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16: 1936-1947, 2005. (Pubitemid 41716424)
23. Wu H, Lu D, Jiang H, et al: Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 25: 130-139, 2008. (Pubitemid 351252578)
24. Eto M, Kozai T, Cosentino F, Joch H and Lüscher TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759, 2002. (Pubitemid 34408880)
25. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K and Kume H: Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 35: 722-729, 2006. (Pubitemid 44901862)
26. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al: Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291: L668-L676, 2006. (Pubitemid 44498478)
27. Weis M, Heeschen C, Glassford AJ and Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 105: 739-745, 2002. (Pubitemid 34157379)
28. Hanai JI, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P and Sukhatme VP: Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways. J Cell Physiol 227: 1709-1720, 2012.
29. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ and Arcaro A: Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25: 877-887, 2006. (Pubitemid 43237706)
30. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T and Hayakawa M: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10: 8648-8655, 2004. (Pubitemid 40053433)
31. Sanli T, Liu C, Rashid A, et al: Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 6: 439-450, 2011.
32. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M and O'Donovan N: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 8: 9, 2008.
33. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S and Chayama K: Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 69: 1547-1555, 2005. (Pubitemid 41743974)
34. Medina RJ, O'Neill CL, Devine AB, Gardiner TA and Stitt AW: The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 3: e2584, 2008.
35. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
36. Foster KA, Oster CG, Mayer MM, Avery ML and Audus KL: Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 243: 359-366, 1998. (Pubitemid 28488846)
37. Hoshino Y, Mio T, Nagai S, Miki H, Ito I and Izumi T: Cytotoxic effects of cigarette smoke extract on an alveolar type II cellderived cell line. Am J Physiol Lung Cell Mol Physiol 281: L509-L516, 2001.
38. Kannan S, Huang H, Seeger D, et al: Alveolar epithelial type II cells activate alveolar macrophages and mitigate P. Aeruginosa infection. PLoS One 4: e4891, 2009.
39. Bhaskaran M, Kolliputi N, Wang Y, Gou D, Chintagari NR and Liu L: Trans-differentiation of alveolar epithelial type II cells to type I cells involves autocrine signaling by transforming growth factor beta 1 through the Smad pathway. J Biol Chem 282: 3968-3976, 2007. (Pubitemid 47084485)